Luminex Corporation Begins Clinical Trials for ARIES™ GBS Assay
News Jun 09, 2015
Luminex Corporation has announced that it has commenced clinical and analytical studies to evaluate the company's ARIES™ Group B Streptococcus (GBS) Assay.
"We continue to build momentum in our commercial launch schedule for the ARIES platform with the start of clinical trials for GBS, the third assay in the ARIES pipeline," said Homi Shamir, President and CEO of Luminex. "The progression of our ARIES menu with assays that are important to patient care continues and the Group B Strep assay is a key contributor due to the high prevalence and potentially serious or life threatening consequences to newborns."
The clinical trials for the ARIES GBS Assay are being conducted at several clinical laboratories in the U.S., and Luminex still expects its FDA submission for the ARIES platform and ARIES HSV 1&2 Assay to occur in the summer of 2015.
Cancer Cells’ Energy Source Blocked by Natural CompoundNews
Researchers have not only untangled an unusual wiring system that cancer cells use for carbohydrate metabolism, but also identified a natural compound that appears to selectively shut down this system in laboratory studies.READ MORE
Drug Discovery Alliance Formed to Help Increase Drug Development Success RateNews
Two prominent preclinical safety companies have launched a unique European alliance to address the high safety-related failure rate in drug development.READ MORE